CARMAT Completes Enrolment in the EFICAS Clinical Study and Receives Approval From French Authorities for 21 Additional Aeson® Implants, While Awaiting Potential Reimbursement of the Device in France
PARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the completion of enrolment of the 52 patients planned in the EFICAS study, and the approval from the French authorities to perform 21 additional Aeson® implants, while awaiting potential reimbursement of the device in France.
Stéphane Piat, Chief Executive Officer of CARMA, commented: 'The very strong momentum in the EFICAS study, which enrolment is now complete, reflects the quality and performance of our Aeson® artificial heart and its ability to address the unmet need expressed by healthcare professionals and patients. I am convinced that this study paves the way for strong sales development in Europe and beyond - particularly once its results will have been published, hopefully as soon as end of 2025.
I am also very pleased that, by approving 21 additional implants, the French authorities enable patients in France to continue benefitting from our therapy beyond the EFICAS study. This is a strong sign of confidence in Aeson® artificial heart.
Given the study design, we anticipate to be in a position to file for Aeson®'s reimbursement in France early next year, which could lead to coverage of our artificial heart by the French Social Security system during 2026.
The EFICAS study is also important given our strategy to access the U.S. market, which we are expecting to achieve in 2028.
I would like to thank all patients and healthcare professionals, as well as our teams for their contribution to this important step in Aeson®'s development.'
Enrolment completed in the EFICAS study
Initiated in November 2022, the EFICAS clinical study is the largest ever one conducted by CARMAT. It involves 52 patients eligible for a heart transplant and is carried out across 10 hospitals in France 1.
The primary endpoint of EFICAS is patient survival at 6 months post-Aeson® implant, without disabling stroke, or a successful heart transplant within that period.
EFICAS is key to support Aeson®'s commercial rollout in Europe 2 (through 'evidence-based medicine'), and secure its reimbursement in France, and is also expected to contribute to securing the Pre-Market Approval (PMA) in the United States, currently targeted for 2028 3.
Given the 6-month post-implant follow-up of patients, CARMAT expects completing the EFICAS study (primary endpoint) early November 2025, which will be followed by the publication of its results.
Approval obtained from French authorities for 21 additional Aeson® implants - and filing for reimbursement in France planned early 2026
As a reminder, the EFICAS study is partially funded by the French State (€13 million for 52 implants 4), through the 'Forfait Innovation' program.
In order to allow patients in France to continue benefitting from Aeson® artificial heart after the completion of the 52 implants in the EFICAS study, the French authorities 5 have approved 21 additional implants, under financial terms equivalent to those of the 'Forfait Innovation.
In parallel, CARMAT is taking all necessary steps to be in position to submit a reimbursement application (so-called 'LPPR') for Aeson® at the beginning of 2026, which could allow Aeson® to be covered by the French Social Security system during the same year.
Disclaimer
This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country.
This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT (www.carmatsa.com/en/) and the AMF (www.amf-france.org).
Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today.
Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 hours ago
- Business Wire
2025 Zhejiang (Egypt) International Engineering Exhibition Successfully Held
RIYADH, Saudi Arabia & CAIRO--(BUSINESS WIRE)--From June 17th to 19th, 2025, the Zhejiang (Egypt) International Engineering Exhibition was successfully held in Hall 3 of the Cairo International Exhibition Center. Hosted by the Department of Commerce of Zhejiang Province and organized by the Zhejiang International Contractors Association and Hangzhou Boheng Business Exhibition Co., Ltd., the exhibition was held alongside the prominent 2025 Egypt Big 5 Construction Show. Zhejiang showcased its unified provincial image through a dedicated area featuring 10 enterprises, 15 representatives, and an exhibition space of 108 square meters. Participating companies included Yoking Pump Co., Ltd., Zhitao Electric Group Co., Ltd., Zhejiang Qiankai Electric Equipment Co., Ltd., and Hangzhou Fulltime Robotics Co., Ltd. Over three days, Zhejiang enterprises interacted with more than 920 professional merchants from 12 countries and regions, resulting in intended transaction amounts of $5.7 million. Strategically located at the crossroads of Asia, Africa, and Europe, Egypt plays a key role in the Belt and Road Initiative. In May 2024, China and Egypt signed the Cooperation Plan on Jointly Promoting the Construction of the Belt and Road Initiative, which defined key cooperation areas. This strengthened framework will deepen collaboration and fuel development. To diversify its economy, Egypt has initiated projects like 'Egypt Vision 2030,' the New Administrative Capital, and the Suez Canal Corridor—sectors with strong demand for construction and renewable energy. These developments open new avenues for Zhejiang enterprises to participate in Egypt's infrastructure upgrades. Zhejiang Province has been advancing its 'Sweet Potato Economy' strategy to upgrade the 'No. 1 Opening-Up Project.' In 2024, newly signed foreign contracting projects totaled $5.486 billion (up 11.57%), with a completed turnover of $7.995 billion (up 15.27%), ranking fourth nationwide in business scale. This Egyptian exhibition marked Zhejiang's first self-organized overseas event in 2025. Themed 'Shaping a Smart, Green Future with Zhejiang,' it underscored the province's capabilities in green technology and smart construction. Zhejiang will continue to leverage overseas exhibitions to help more enterprises expand globally, foster cooperation and technology exchange, and offer sustainable solutions to global engineering challenges.
Business Wire
10 hours ago
- Business Wire
U-Haul Offers Disaster Relief After Derecho Hits North Dakota, Minnesota
FARGO, N.D.--(BUSINESS WIRE)--U-Haul ® is extending 30 days of free self-storage and U-Box ® container usage at seven centers across eastern North Dakota and northern Minnesota to residents affected by tornadoes that left a wide path of destruction Friday night and into the early hours of Saturday. U-Haul is extending 30 days of free self-storage and U-Box container usage at seven centers in North Dakota and Minnesota to residents impacted by the derecho. Share A derecho with winds exceeding 100 mph moved across numerous counties in both states, damaging properties and leaving thousands without power. There were multiple tornado sightings throughout the fast-moving storm system. Enderlin, N.D., located southwest of Fargo, and Bemidji, Minn., were among the communities hardest hit. Access to dry and secure self-storage and portable storage containers can be vital to communities during the clean-up and recovery process after natural disasters. The 30 days free offer applies to new self-storage and U-Box rentals and is based on availability. The U-Box offer is for on-site storage at Company centers, and for customers who tow their portable storage container. U-Box delivery and pick-up is also available for a modest cost. People seeking more information on the disaster relief program or needing to arrange storage services can contact the nearest participating U-Haul facility: NORTH DAKOTA U-Haul Moving & Storage of 13th Ave. 4901 13th Ave S. Fargo, ND 58103 (701) 205-3260 U-Haul Moving & Storage of Fargo 1436 Main Ave. Fargo, ND 58103 (701) 293-5256 U-Haul Moving & Storage of Osgood 5200 Veterans Blvd. Fargo, ND 58104 (701) 492-8900 U-Haul Storage of Fargo 610 42nd St. N. Fargo, ND 58102 (701) 639-7714 MINNESOTA U-Haul Moving & Storage of Moorhead 50 County Road 9 Dilworth, MN 56529 (218) 303-1480 U-Haul Storage of Nisswa 4745 County Road 77 Nisswa, MN 56468 (218) 963-5106 U-Haul Storage North Baxter 15237 Edgewood Dr. Brainerd, MN 56401 (218) 297-3018 In addition to its 30 days free self-storage disaster relief program, U-Haul is proud to be at the forefront of aiding communities in times of need as an official American Red Cross Disaster Responder. About U-HAUL Celebrating our 80th anniversary in 2025, U-Haul is the No. 1 choice of do-it-yourself movers with more than 24,000 rental locations across all 50 states and 10 Canadian provinces. The U-Haul app makes it easy for customers to use U-Haul Truck Share 24/7 to access trucks anytime through the self-dispatch and -return options on their smartphones with our patented Live Verify technology. Our customers' patronage has enabled the U-Haul fleet to grow to 193,900 trucks, 138,200 trailers and 40,300 towing devices. U-Haul is the third largest self-storage operator in North America and offers 1,060,000 rentable storage units and 92.0 million square feet of self-storage space at owned and managed facilities. U-Haul is the top retailer of propane in the U.S. and the largest installer of permanent trailer hitches in the automotive aftermarket industry. Get the U-Haul app from the App Store or Google Play.
Newsweek
12 hours ago
- Newsweek
French Scientists Discover New Blood Group
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A group of French researchers have discovered a new, "ultra rare" blood group in a Guadeloupean woman after years of researching and sequencing her blood, the French Blood Establishment (EFS) said in a Friday press release. Newsweek has reached out to EFS's press team for comment via email on Saturday. Why It Matters The discovery marks the 48th known blood group system in the world. Understanding blood types is critical for ensuring safe and effective transfusions and organ transplants, as well as identifying certain health risks. Blood classification helps medical providers determine compatibility—or lack thereof—between donors and recipients. There are approximately 14 million units of blood transfused annually in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC). Outside of the well-known ABO system, there are a series of rare blood groups. What To Know In a social media post on LinkedIn, the EFS said in French that "this discovery was officially recognized in early June in Milan by the International Society of Blood Transfusion (ISBT)." The woman is the only known carrier of a rare blood type called "Gwada negative." The case first drew attention in 2011 when she required a blood transfusion, but no compatible donor could be found. Researchers later revisited her case in 2019 and identified the unique blood type through further analysis, according to the EFS's Friday press release. Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told Agence France-Presse (AFP) that a "very unusual" antibody was found in the patient's blood in 2011. She was 54 years old at the time when she underwent a series of tests prior to surgery, according to Le Monde. Due to limited resources at the time, research into her blood type had been halted. Peyrard said the woman inherited the blood type from her parents who had the mutated gene. EFS, in French, said that the discovery "brings hope to patients, especially those with a rare blood type. Remember that the safety of a transfusion depends on the compatibility of blood groups." The group says it has been responsible for identifying 10 of the past 17 blood group systems discovered in the past decade. Karl Landsteiner discovered the first blood groups in the early 1900s and was awarded the Nobel Prize in 1930 for his work. Serum tubes with blood samples from patients are processed in the central medical laboratory of the St. Georg Clinic in Leipzig. Serum tubes with blood samples from patients are processed in the central medical laboratory of the St. Georg Clinic in Leipzig. Waltraud Grubitzsch/picture-alliance/dpa/AP Images What People Are Saying The official Nobel Prize account posted on X, formerly Twitter, on June 17: "The discovery of blood groups completely changed the view on blood transfusions, and it didn't take long before the first successful attempts were carried out. During WWI, blood transfusions were first performed on a large scale. Countless lives were also saved through surgeries, which previously had been unfeasible due to the blood loss involved." What Happens Next? Scientists continue to study blood types, advancing global health care and improving the precision and effectiveness of transfusions.
